X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SUN PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SUN PHARMA CIPLA/
SUN PHARMA
 
P/E (TTM) x 33.8 40.8 82.8% View Chart
P/BV x 3.5 3.3 105.6% View Chart
Dividend Yield % 0.4 0.7 52.9%  

Financials

 CIPLA   SUN PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
SUN PHARMA
Mar-17
CIPLA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs622842 73.9%   
Low Rs458572 80.1%   
Sales per share (Unadj.) Rs181.9131.6 138.2%  
Earnings per share (Unadj.) Rs12.932.7 39.4%  
Cash flow per share (Unadj.) Rs29.338.0 77.2%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.40.5 74.8%  
Book value per share (Unadj.) Rs155.7152.7 101.9%  
Shares outstanding (eoy) m804.512,399.26 33.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.05.4 55.3%   
Avg P/E ratio x42.021.6 194.0%  
P/CF ratio (eoy) x18.418.6 98.9%  
Price / Book Value ratio x3.54.6 74.9%  
Dividend payout %15.510.7 145.2%   
Avg Mkt Cap Rs m434,5161,696,877 25.6%   
No. of employees `00023.017.5 131.6%   
Total wages/salary Rs m26,33849,023 53.7%   
Avg. sales/employee Rs Th6,349.118,028.3 35.2%   
Avg. wages/employee Rs Th1,143.02,798.8 40.8%   
Avg. net profit/employee Rs Th449.34,479.5 10.0%   
INCOME DATA
Net Sales Rs m146,302315,784 46.3%  
Other income Rs m2,2876,232 36.7%   
Total revenues Rs m148,589322,016 46.1%   
Gross profit Rs m24,758100,893 24.5%  
Depreciation Rs m13,22912,648 104.6%   
Interest Rs m1,5943,998 39.9%   
Profit before tax Rs m12,22290,479 13.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-7099 -70.4%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,79812,116 14.8%   
Profit after tax Rs m10,35478,462 13.2%  
Gross profit margin %16.931.9 53.0%  
Effective tax rate %14.713.4 109.8%   
Net profit margin %7.124.8 28.5%  
BALANCE SHEET DATA
Current assets Rs m87,370329,537 26.5%   
Current liabilities Rs m33,081178,870 18.5%   
Net working cap to sales %37.147.7 77.8%  
Current ratio x2.61.8 143.4%  
Inventory Days Days8779 110.1%  
Debtors Days Days6283 74.8%  
Net fixed assets Rs m111,567204,766 54.5%   
Share capital Rs m1,6092,399 67.1%   
"Free" reserves Rs m123,645363,997 34.0%   
Net worth Rs m125,254366,397 34.2%   
Long term debt Rs m36,45414,361 253.8%   
Total assets Rs m209,532614,102 34.1%  
Interest coverage x8.723.6 36.7%   
Debt to equity ratio x0.30 742.5%  
Sales to assets ratio x0.70.5 135.8%   
Return on assets %5.713.4 42.5%  
Return on equity %8.321.4 38.6%  
Return on capital %8.524.8 34.2%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06644,118 115.7%   
Fx outflow Rs m17,67824,484 72.2%   
Net fx Rs m33,38819,634 170.1%   
CASH FLOW
From Operations Rs m23,82470,822 33.6%  
From Investments Rs m-13,127-42,216 31.1%  
From Financial Activity Rs m-13,239-22,854 57.9%  
Net Cashflow Rs m-2,4786,107 -40.6%  

Share Holding

Indian Promoters % 16.0 63.7 25.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.1 237.8%  
FIIs % 23.7 23.0 103.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 8.3 315.7%  
Shareholders   161,166 133,026 121.2%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Extend Gains; Energy & PSU Stocks Rally(12:30 pm)

Stock markets in India continue to trade higher taking cues from their key Asian counterparts. Sectoral indices are trading in green with stocks in the oil & gas sector.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


May 28, 2018 03:07 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS